HK1195903A1 - -氨基- 吡啶- -基 -二氫- -噁嗪衍生物及其作為 和/或 抑制劑的用途 - Google Patents

-氨基- 吡啶- -基 -二氫- -噁嗪衍生物及其作為 和/或 抑制劑的用途

Info

Publication number
HK1195903A1
HK1195903A1 HK14109142.2A HK14109142A HK1195903A1 HK 1195903 A1 HK1195903 A1 HK 1195903A1 HK 14109142 A HK14109142 A HK 14109142A HK 1195903 A1 HK1195903 A1 HK 1195903A1
Authority
HK
Hong Kong
Prior art keywords
bace
pyridin
dihydro
inhibitors
amino
Prior art date
Application number
HK14109142.2A
Other languages
English (en)
Inventor
Rainer Martin Lueoend
Rainer Machauer
Heinrich Rueeger
Siem Jacob Veenstra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47018309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1195903(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1195903A1 publication Critical patent/HK1195903A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14109142.2A 2011-08-25 2014-09-10 -氨基- 吡啶- -基 -二氫- -噁嗪衍生物及其作為 和/或 抑制劑的用途 HK1195903A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527172P 2011-08-25 2011-08-25
US201261665395P 2012-06-28 2012-06-28
PCT/IB2012/054269 WO2013027188A1 (en) 2011-08-25 2012-08-23 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors

Publications (1)

Publication Number Publication Date
HK1195903A1 true HK1195903A1 (zh) 2014-11-28

Family

ID=47018309

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14109142.2A HK1195903A1 (zh) 2011-08-25 2014-09-10 -氨基- 吡啶- -基 -二氫- -噁嗪衍生物及其作為 和/或 抑制劑的用途

Country Status (28)

Country Link
US (2) US9163011B2 (zh)
EP (2) EP3023423B1 (zh)
JP (1) JP5816369B2 (zh)
KR (1) KR101601571B1 (zh)
CN (1) CN103906748B (zh)
AP (1) AP2014007507A0 (zh)
AR (1) AR087668A1 (zh)
AU (1) AU2012298177B2 (zh)
BR (1) BR112014004131A2 (zh)
CA (1) CA2845093A1 (zh)
CL (1) CL2014000458A1 (zh)
CO (1) CO6890097A2 (zh)
CR (1) CR20140084A (zh)
EA (1) EA024580B1 (zh)
ES (2) ES2565229T3 (zh)
GT (1) GT201400031A (zh)
HK (1) HK1195903A1 (zh)
IL (1) IL230975A0 (zh)
MA (1) MA35356B1 (zh)
MX (1) MX339303B (zh)
PE (1) PE20141540A1 (zh)
PL (1) PL2748162T3 (zh)
SG (1) SG2014012108A (zh)
TN (1) TN2014000062A1 (zh)
TW (1) TW201313706A (zh)
UY (1) UY34278A (zh)
WO (1) WO2013027188A1 (zh)
ZA (1) ZA201401139B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2727859C (en) 2008-06-13 2016-11-01 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
ES2590038T5 (es) † 2009-12-11 2021-10-19 Shionogi & Co Derivado de oxazina
MY162413A (en) 2011-01-13 2017-06-15 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
CA2902212C (en) * 2013-03-01 2020-10-13 Amgen Inc. Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
MA38556A1 (fr) * 2013-04-11 2017-09-29 Hoffmann La Roche Inhibiteurs de bace1
TWI639607B (zh) 2013-06-18 2018-11-01 美國禮來大藥廠 Ｂａｃｅ抑制劑
WO2015124576A1 (en) 2014-02-19 2015-08-27 H. Lundbeck A/S 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
CN106795147B (zh) 2014-08-08 2020-09-22 美国安进公司 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3590512A1 (en) * 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
TW201718543A (zh) 2015-08-12 2017-06-01 Ｈ 朗德貝克公司 作爲ｂａｃｅ１抑制劑之２－胺基－３－氟－３－（氟甲基）－６－甲基－６－苯基－３，４，５，６－四氫吡啶
EP3423450B1 (en) * 2016-03-01 2019-11-27 H. Hoffnabb-La Roche Ag Bace 1 inhibitors
MX2019007102A (es) 2016-12-15 2019-12-16 Amgen Inc Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX2019007100A (es) 2016-12-15 2019-12-16 Amgen Inc Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
MX2019007104A (es) 2016-12-15 2019-11-05 Amgen Inc Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso.
JP7177773B2 (ja) * 2016-12-15 2022-11-24 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのオキサジン誘導体および使用方法
AU2017378316B2 (en) 2016-12-15 2021-04-01 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
AU2019258575A1 (en) 2018-04-27 2020-10-29 Shionogi & Co., Ltd. Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity
CN109725092A (zh) * 2019-03-19 2019-05-07 北京和合医学诊断技术股份有限公司 检测血液中齐拉西酮含量的液相色谱分析方法
CN113173852B (zh) * 2021-04-26 2022-07-12 深圳市华先医药科技有限公司 二氟丙二酸酯类化合物的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (zh) 1968-08-31 1970-03-03
WO2003006426A1 (en) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Aromatic guanylhydrazones as effective compounds against neurodiseases
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
RU2374241C2 (ru) 2003-05-20 2009-11-27 Новартис Аг N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы
EP2597087B1 (en) 2005-10-25 2016-03-30 Shionogi&Co., Ltd. Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
EP2147914B1 (en) * 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
JPWO2010047372A1 (ja) * 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
WO2010063718A1 (en) 2008-12-02 2010-06-10 ETH Zürich Screening assay for metabolic disease therapeuticals
US8461160B2 (en) * 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
ES2590038T5 (es) 2009-12-11 2021-10-19 Shionogi & Co Derivado de oxazina
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
MX2013008192A (es) 2011-01-13 2013-12-16 Novartis Ag Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
EP2665716B1 (en) 2011-01-21 2017-03-08 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
US8404680B2 (en) 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
KR20140041590A (ko) 2011-06-07 2014-04-04 에프. 호프만-라 로슈 아게 [1,3]옥사진
KR20140041687A (ko) 2011-06-07 2014-04-04 에프. 호프만-라 로슈 아게 Bace1 및/또는 bace2 억제제로서의 할로겐-알킬-1,3-옥사진

Also Published As

Publication number Publication date
PL2748162T3 (pl) 2016-06-30
AU2012298177B2 (en) 2015-10-29
WO2013027188A1 (en) 2013-02-28
CN103906748A (zh) 2014-07-02
SG2014012108A (en) 2014-05-29
NZ621093A (en) 2015-05-29
IL230975A0 (en) 2014-03-31
EA201490491A1 (ru) 2014-06-30
CR20140084A (es) 2014-05-02
PE20141540A1 (es) 2014-10-31
EP3023423A1 (en) 2016-05-25
TW201313706A (zh) 2013-04-01
MX2014002230A (es) 2014-04-25
CA2845093A1 (en) 2013-02-28
KR101601571B1 (ko) 2016-03-08
AP2014007507A0 (en) 2014-03-31
US20150150877A1 (en) 2015-06-04
CN103906748B (zh) 2017-06-16
US20130172331A1 (en) 2013-07-04
ES2565229T3 (es) 2016-04-01
CO6890097A2 (es) 2014-03-10
JP2014524463A (ja) 2014-09-22
EA024580B1 (ru) 2016-09-30
JP5816369B2 (ja) 2015-11-18
AR087668A1 (es) 2014-04-09
ES2638832T3 (es) 2017-10-24
BR112014004131A2 (pt) 2017-06-13
MA35356B1 (fr) 2014-08-01
EP2748162B1 (en) 2015-12-16
KR20140054313A (ko) 2014-05-08
GT201400031A (es) 2015-02-19
CL2014000458A1 (es) 2014-09-05
AU2012298177A1 (en) 2014-03-06
MX339303B (es) 2016-05-19
TN2014000062A1 (en) 2015-07-01
EP2748162A1 (en) 2014-07-02
EP3023423B1 (en) 2017-05-31
UY34278A (es) 2013-04-05
US9163011B2 (en) 2015-10-20
ZA201401139B (en) 2014-12-23

Similar Documents

Publication Publication Date Title
HK1195903A1 (zh) -氨基- 吡啶- -基 -二氫- -噁嗪衍生物及其作為 和/或 抑制劑的用途
ZA201308400B (en) 1,3-oxazines as bace1 and/or bace2 inhibitors
IL228104A0 (en) 3, 1 oxazolines as 1bace and/or 2bace inhibitors
BR112013016360A2 (pt) 1,4 oxazinas como inibidores de bace1 e/ou bace2
IL229686A0 (en) Halogen-alkyl-3,1 oxazines as 1bace and/or bacce2 inhibitors
BR112013014610A2 (pt) 1,4 oxazinas como inibidores de bace1 e/ou bace2
HK1207369A1 (zh) -苯氧基- -嘧啶- -酮衍生物及其用作 逆轉錄酶抑制劑
EP2908825A4 (en) TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND USE THEREOF
EP2908824A4 (en) TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND USE THEREOF
EP2694489A4 (en) C5-C6-OXACYCLUS-Fused Thiadiazinyl-oxime Compounds as Bace Inhibitors, and Compositions Therefor, and Their Use
EP2694521A4 (en) PYRROLIDIN-CONDENSED THIADIAZINOXIDE COMPOUNDS AS BACE HEMMER, COMPOSITIONS AND THEIR USE
BR112013020019A2 (pt) 1,4-oxazepinas como inibidores de bace1 e/ou bace2.
IL227406A (en) Pyrimidine Gyrase and Topoisemarase Suppressors IV preparations containing them and their uses
HRP20180543T1 (hr) Spojevi uree i njihova upotreba kao inhibitora enzima
HK1198365A1 (zh) 咪唑並吡啶化合物、組合物和使用方法
ZA201405227B (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
ZA201309171B (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190822